Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Gastric Ulcers Overview | 6 | 1 |
Therapeutics Development | 7 | 1 |
Pipeline Products for Gastric Ulcers Overview | 7 | 1 |
Gastric Ulcers Therapeutics under Development by Companies | 8 | 1 |
Gastric Ulcers Pipeline Products Glance | 9 | 2 |
Clinical Stage Products | 9 | 1 |
Early Stage Products | 10 | 1 |
Gastric Ulcers Products under Development by Companies | 11 | 1 |
Gastric Ulcers Companies Involved in Therapeutics Development | 12 | 5 |
Ache Laboratorios Farmaceuticos S/A | 12 | 1 |
Astellas Pharma Inc. | 13 | 1 |
ChoDang Pharm Co., Ltd. | 14 | 1 |
Kukje Pharmaceutical Industry Co., Ltd. | 15 | 1 |
XuanZhu Pharma Co., Ltd. | 16 | 1 |
Gastric Ulcers Therapeutics Assessment | 17 | 8 |
Assessment by Monotherapy Products | 17 | 1 |
Assessment by Combination Products | 18 | 1 |
Assessment by Target | 19 | 2 |
Assessment by Mechanism of Action | 21 | 2 |
Assessment by Route of Administration | 23 | 1 |
Assessment by Molecule Type | 24 | 1 |
Drug Profiles | 25 | 7 |
(ecabet + ranitidine) Drug Profile | 25 | 1 |
anaprazole sodium Drug Profile | 26 | 1 |
ASP-6537 Drug Profile | 27 | 1 |
KJ-14001 Drug Profile | 28 | 1 |
PDI-39 Drug Profile | 29 | 1 |
PMKS-005 Drug Profile | 30 | 1 |
Small Molecules for Gastric Ulcers Drug Profile | 31 | 1 |
Gastric Ulcers Dormant Projects | 32 | 1 |
Gastric Ulcers Discontinued Products | 33 | 1 |
Gastric Ulcers Product Development Milestones | 34 | 8 |
Featured News &Press Releases | 34 | 1 |
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies | 34 | 1 |
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck | 35 | 1 |
Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations | 35 | 1 |
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy | 35 | 1 |
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck &Co., Inc. | 36 | 1 |
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) | 37 | 1 |
Jun 01, 2007: AstraZeneca s Prilosec Patents Upheld By Court | 37 | 1 |
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court | 38 | 1 |
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals | 38 | 1 |
Oct 23, 2001: Prilosec US litigation | 39 | 1 |
May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec | 39 | 1 |
May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent | 39 | 1 |
Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement | 39 | 1 |
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada | 40 | 1 |
Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy | 40 | 2 |
Appendix | 42 | 2 |
Methodology | 42 | 1 |
Coverage | 42 | 1 |
Secondary Research | 42 | 1 |
Primary Research | 42 | 1 |
Expert Panel Validation | 42 | 1 |
Contact Us | 42 | 1 |
Disclaimer | 43 | 1 |